CDKN2B and hepatocellular carcinoma: Although the treatment with IFN-γ alone did not induce significant senescence or apoptosis (Figure 1, Supplementary Figure 1 and data not shown), we found that adding IFN-γ to trastuzumab and pertuzumab increased SA-β-gal staining (Figure 8A), p15INK4b expression and cleaved caspase-3 expression in SK-BR-3 (Figure 8B) and HCC-1419 (Figure 8C) cells.